Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Ugo Testa, Elvira Pelosi, Arthur E. Frankel
Biomarker Research (2014) Vol. 2, Iss. 1
Open Access | Times Cited: 230

Showing 1-25 of 230 citing articles:

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju, Andrew A. Lane, Kendra Sweet, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 17, pp. 1628-1637
Open Access | Times Cited: 345
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth
Daniele Bellavia, Stefania Raimondo, Giovanna Calabrese, et al.
Theranostics (2017) Vol. 7, Iss. 5, pp. 1333-1345
Open Access | Times Cited: 318
Advances in acute myeloid leukemia
Laura F. Newell, Rachel J. Cook
BMJ (2021), pp. n2026-n2026
Open Access | Times Cited: 311
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Nicholas J. Short, Marina Konopleva, Tapan M. Kadia, et al.
Cancer Discovery (2020) Vol. 10, Iss. 4, pp. 506-525
Open Access | Times Cited: 290
Molecular biomarkers in acute myeloid leukemia
Jeanette Prada-Arismendy, Johanna C. Arroyave-Ospina, Sarah Röthlisberger
Blood Reviews (2016) Vol. 31, Iss. 1, pp. 63-76
Closed Access | Times Cited: 277
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, et al.
Blood (2020) Vol. 137, Iss. 6, pp. 751-762
Open Access | Times Cited: 262
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Arthur E. Frankel, Jung Hee Woo, Chul Ahn, et al.
Blood (2014) Vol. 124, Iss. 3, pp. 385-392
Open Access | Times Cited: 215
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana, Saar Gill
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 184
Emerging concepts of type I interferons in SLE pathogenesis and therapy
Antonios Psarras, Miriam Wittmann, Edward M Vital
Nature Reviews Rheumatology (2022)
Closed Access | Times Cited: 96
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
Laurent Gauthier, Angéla Virone-Oddos, Jochen Beninga, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 9, pp. 1296-1306
Open Access | Times Cited: 65
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Naval Daver, Pau Montesinos, Daniel J. DeAngelo, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 3, pp. 388-399
Closed Access | Times Cited: 24
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili, Ling Huang, Hua Li, et al.
Science Translational Medicine (2015) Vol. 7, Iss. 289
Closed Access | Times Cited: 158
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Yelena Kovtun, Gregory E. Jones, Sharlene Adams, et al.
Blood Advances (2018) Vol. 2, Iss. 8, pp. 848-858
Open Access | Times Cited: 156
An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Steven R. Leong, Siddharth Sukumaran, Maria Hristopoulos, et al.
Blood (2016) Vol. 129, Iss. 5, pp. 609-618
Open Access | Times Cited: 143
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Ugo Testa, Elvira Pelosi, Germana Castelli
Cancers (2019) Vol. 11, Iss. 9, pp. 1358-1358
Open Access | Times Cited: 130
Recent developments in immunotherapy of acute myeloid leukemia
Felix S. Lichtenegger, Christina Krupka, Sascha Haubner, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 128
CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
A.E. Bras, Valérie de Haas, Arthur van Stigt, et al.
Cytometry Part B Clinical Cytometry (2018) Vol. 96, Iss. 2, pp. 134-142
Open Access | Times Cited: 108
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
Jessica C. Petrov, M. Wada, Kevin G. Pinz, et al.
Leukemia (2018) Vol. 32, Iss. 6, pp. 1317-1326
Open Access | Times Cited: 100
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
Juanjuan Zhao, Yongping Song, Delong Liu
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 95
Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
Fu Li, May Kung Sutherland, Changpu Yu, et al.
Molecular Cancer Therapeutics (2017) Vol. 17, Iss. 2, pp. 554-564
Open Access | Times Cited: 90
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
Alessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 85
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
Nidhi Jyotsana, Amit Sharma, Anuhar Chaturvedi, et al.
Annals of Hematology (2019) Vol. 98, Iss. 8, pp. 1905-1918
Open Access | Times Cited: 80
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities
Eimear O’Reilly, Hojjat Alizadeh Zeinabad, Éva Szegezdi
Blood Reviews (2021) Vol. 50, pp. 100850-100850
Open Access | Times Cited: 58
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu, Hao Zhang, Hui Cao, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 47
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
Elvira Pelosi, Germana Castelli, Ugo Testa
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2718-2718
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top